The state-backed Food and Environment Reseach Agency remains a shareholder in Forsite having taken a stake when the portfolio company was spun out from the UK's agriculature department in 2007.
Abingdon Health, a portfolio company of UK-listed university technology commercialization and investment group Imperial Innovations, has made an investment and acquired a controlling 80% interest in Forsite Diagnostics, a local medical contract developer.
The state-backed Food and Environment Reseach Agency remains a shareholder in Forsite having taken a stake when the portfolio company was spun out from the UK’s agriculature department in 2007.
UK-based Abingdon Health commercialises a portfolio of novel clinical diagnostics technologies and in March took a similar controlling stake in Molecular Vision after raising £3m from a consortium led by Imperial Innovations.
In November 2010, Abingdon set up a joint venture, Bioscience Ventures, with the University of Birmingham, which last year led to a urine test for adrenal cancer being developed.
